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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
02.11.2020 T cell 
immunity 
against 
SARS-CoV-
2 is likely to 
be present 
within most 
adults six 
months 
after 
primary 
infection 
bioRxiv | pre-
print (non-
peer 
reviewed) 
• A robust T cell response at 
six months after SARS-CoV-
2 infection in individuals who 
had experienced either 
mild/moderate symptoms or 
were asymptomatic  
• Study in 100 individuals, one 
of the largest reported in this 
field 
• The T cell response was 
directed against a range of 
proteins from the virus, 
including the spike protein 
used in most vaccine studies, 
but also comparably against 
other proteins, such as 
nucleoprotein, which could be 
considered in future vaccine 
protocols 
• The size of the T cell 
response was higher in 
people who had experienced 
symptomatic infection 
compared with asymptomatic 
cases six months previously 
• Cellular immunity was 
strongly correlated with the 
peak level of the antibody 
response, with larger cellular 
T cell 
immunity 
responses appearing to 
protect against antibody 
‘waning’ over time, 
suggesting the importance of 
vaccine-induced cellular 
immune responses 
28.10.2020 Robust 
neutralizing 
antibodies 
to SARS-
CoV-2 
infection 
persist for 
months 
Science | 
Report 
• This study reports that of 
30,082 individuals screened 
at Mount Sinai Health 
Systems in New York City, 
the vast majority of infected 
individuals with mild-to-
moderate COVID-19 have 
robust IgG antibodies against 
the viral spike protein that 
persist for at least 5 months 
and which correlate 
significantly with neutralising 
antibody responses 
• Data suggests that more than 
90% of seroconverters make 
detectible neutralising 
antibody responses 
• Although this is not 
conclusive evidence that 
these antibody responses 
protect from reinfection, 
authors believe that is it is 
very likely that they will 
decrease the odds ratio of 
reinfection, and may 
attenuate disease in the case 
of breakthrough infection 
Antibody 
response 
27.10.2020 Declining 
prevalence 
of antibody 
positivity to 
SARS-CoV-
2: a 
community 
study of 
356,000 
adults 
medRxiv | 
pre-print (non-
peer 
reviewed) 
• A cross-sectional study of 
365,104 adults between 20 
June and 28 September 
using a self-administered 
lateral flow immunoassay test 
for IgG shows that antibody 
positivity to SARS-CoV-2 
may not persist beyond about 
3 months after infection  
• Antibody positivity was 
greater in those who reported 
a positive PCR and lower in 
older people and those with 
asymptomatic infection 
Antibody 
response 
26.10.2020 Longitudinal 
observation 
and decline 
of 
neutralizing 
antibody 
Nature 
Microbiology | 
Article 
• Using sequential serum 
samples from 65 SARS-CoV-
2 infected individuals 
collected up to 94 days post 
onset of symptoms (POS), 
seroconversion (IgM, IgA, 
IgG) was shown in >95% of 
cases and neutralising 
Antibody 
response 
responses 
in the three 
months 
following 
SARS-CoV-
2 infection 
in humans 
antibody responses when 
sampled beyond 8d POS 
• Kinetics of neutralising 
antibody responses is typical 
of an acute viral infection, 
with declining neutralising 
antibody titres observed after 
an initial peak, of which the 
peak is dependent on 
disease severity – noting that 
those who develop a low 
neutralising antibody 
response, titres can return to 
baseline over a relatively 
short period, whereas those 
with a high neutralising 
antibody response than 
maintain high titres, despite 
an initial decline 
• Further studies on samples at 
extended timepoints are 
needed to determine 
longevity of the neutralising 
antibody response and 
threshold for protection from 
reinfection and/or disease 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
31.10.2020 Excess 
mortality during 
the COVID-19 
pandemic in 
Aden 
governorate, 
Yemen: a 
geospatial and 
statistical 
analysis 
medRxiv | 
pre-print (non-
peer 
reviewed) 
• Burden of COVID-19 in 
low-income and conflict-
affected countries remains 
unclear, largely reflecting 
low testing rates 
• To estimate excess 
mortality during the 
epidemic period, this 
study quantified through 
high-resolution satellite 
imagery activity across all 
identifiable cemeteries 
within Aden governorate 
in Yemen and compared 
estimates to Civil Registry 
office records from the city 
• Findings suggest a 
substantial under-
ascertained impact of 
COVID-19 
Burden, 
FCAS 
29.10.2020 COVID-19 
Infection 
Fatality Ratio 
estimates from 
seroprevalence 
ICL | Report 
34 
• Infection fatality ratio is a 
key statistic for estimating 
the burden of COVID-19  
• Previous estimates have 
relied on data early in the 
epidemic or which have 
not fully accounted for 
uncertainty in serological 
test characteristics 
• 10 representative 
antibody surveys were 
identified to obtain 
updated estimates of the 
IFR using a modelling 
framework addressing 
limitations as above 
• Findings include that age-
specific IFRs follow an 
approx. log-linear pattern, 
with the risk of death 
doubling approx. every 8 
years of age 
• In a typical low-income 
country, with a population 
structure skewed towards 
younger individuals, 
overall IFR was found to 
be 0.23% (0.14-0.42 95% 
prediction interval range) 
Infection 
fatality 
ratio 
27.10.2020 SARS-CoV-2 
spike D614G 
variant confers 
enhanced 
replication and 
transmissibility 
bioRxiv | pre-
print (non-
peer 
reviewed) 
• During the evolution of 
SARS-CoV-2 in humans, 
a variant of SARS-CoV-2 
with a D614G substitution 
in the spike protein 
became the predominant 
circulating variant (S-
614G) of the Covid-19 
pandemic 
• Based on animal work in 
this paper, data show that 
this variant provides a real 
competitive advantage in 
vivo (increased replication 
and transmissibility) 
providing an explanation 
for the global 
predominance of S614G 
variant among the SARS-
CoV-2 viruses currently 
circulating  
• The development, 
improvement and 
characterisation of 
suitable animal models 
that together reflect 
SARS-
CoV-2 
variant 
aspects of SARS-CoV-2 
replication, transmission 
and pathogenicity in 
humans will provide a 
platform to assess the 
potential implications of 
future variants 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
28.10.2020 SARS-CoV-
2 
Neutralizing 
Antibody LY-
CoV555 in 
outpatients 
with Covid-
19 
NEJM | 
Original article 
• Interim analysis of a phase 
2 trial, found that one of 
three doses of neutralising 
antibody LY-CoV555 
appeared to accelerate the 
natural decline in viral load 
over time by day 11 
• Patients who received LY-
CoV555 had fewer 
hospitalizations and a lower 
symptom burden than 
those who received 
placebo, with greatest 
effect in high-risk cohorts 
Neutralising 
antibody 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
23.10.2020 Social 
media 
and 
vaccine 
hesitancy 
BMJ Global 
Health | 
Original 
research 
• At national level, the use of 
social media to organise 
offline action is highly 
predictive of the belief that 
vaccinations are unsafe, with 
such beliefs mounting as 
more organisation occurs on 
social media 
• Foreign disinformation 
campaigns online are 
associated with a drop in both 
mean vaccination coverage 
over time and negative 
discussion of vaccines on 
social media  
• A one-point shift upwards in 
the five-point disinformation 
scale is associated with a two-
Vaccine 
hesitancy, 
social 
media 
percentage point drop in 
mean vaccination coverage 
year over year and a 15% 
increase in negative tweets 
about vaccines 
• There is a significant 
relationship between 
organisation on social media 
and public doubts of vaccine 
safety 
• Also a substantial relationship 
between foreign 
disinformation campaigns and 
declining vaccination 
coverage 
Indirect impact of COVID-19 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
30.10.2020 Physical 
inactivity 
and 
sedentary 
behaviours 
in the 
Bangladeshi 
population 
during the 
COVID-19 
pandemic: 
an online 
cross-
sectional 
survey 
Cell | 
Research 
Article 
• Online survey among 2028 
people over 10 days in 
June 2020 during lockdown 
in Bangladesh 
• During lockdown in 
response to the COVID-19 
pandemic, a sizeable 
proportion of Bangladeshi 
people were physically 
inactive and reported 
sedentary behaviours >=8 
h/day 
• Public campaigns and 
media-based interventions 
encouraging home-based 
physical activities should 
be promoted to attenuate 
the impact of lockdown  
Lockdown, 
physical 
inactivity 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
01.11.2020 Psychological 
and social 
impact of 
COVID-19 in 
medRxiv | 
pre-print (non-
• Cross-sectional online 
survey with 1390 
respondents 
• Compared to men, women 
experience a disproportional 
Gendered 
response 
Pakistan: 
need for 
gender 
responsive 
policies 
peer 
reviewed) 
burden of the psychological 
and social impact of the 
pandemic 
• Involving doctors in 
healthcare communication 
targeting women, may help 
• Social media and radio 
messaging my help 
disseminated information 
among men 
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
02.11.2020 Harms of public health interventions against 
covid-19 must not be ignored 
BMJ | Analysis 
30.10.2020 Pandemic or not, experts need to be self-
aware and humble 
Forbes | Blog 
30.10.2020 The science of superspreading Science | Graphic 
30.10.2020 Covid-19 trial begins as Kenya vaccinates its 
first volunteers 
The Star, Kenya | News 
30.10.2020 COVAX welcomes appointment of civil 
society representatives 
CEPI | News 
30.10.2020 COVID-19 human challenge studies in the 
UK 
The Lancet Respiratory 
Medicine | News 
29.10.2020 Build back stronger universal health coverage 
systems after the COVID-19 pandemic: the 
need for better governance and linkage with 
universal social protection 
BMJ Global Health | 
Commentary 
29.10.2020 COVID-19 transmission – up in the air The Lancet Respiratory 
Medicine | Comment 
29.10.2020 Dexamethasone in hospitalised patients with 
COVID-19: addressing uncertainties 
The Lancet Respiratory 
Medicine | Comment 
28.10.2020 No-fault compensation for vaccine injury – the 
other side of equitable access to COVID-19 
vaccines 
NEJM | Perspective 
28.10.2020 The ‘very very bad look’ of remdesivir, the 
first FDA-approved COVID-19 drug 
Science mag | news 
28.10.2020 We must stop flying blind: building on existing 
systems in low- and middle-income countries 
to improve the COVID-19 response 
CGD | Blog 
26.10.2020 Preventing the spread of SARS-CoV-2 with 
masks and other “low-tech” interventions 
JAMA | Viewpoint 
26.10.2020 How should we evaluate lockdowns? 
Disentangling effectiveness, context, and 
politics 
CGD | Blog 
19.10.2020 Shielding the vulnerable – a strategy for long-
term pandemic response 
IDS | Opinion 
Guidelines, Statements & Tools 
 Publication 
Date 
Title/URL Source   Summary 
Ongoing COVID-19 and 
Urban Health 
WHO 
• Includes short case studies on how 
cities around the world have 
responded to COVID-19 challenges, 
WHO guidance and resources on 
COVID-19 relevant to cities and local 
governments 
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Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 Evidence Summary 
y 
C19 Resource Hubs   
Global  Regional 
& Country 
Academic 
journals & 
Publishers 
Institutes/Centres/
Funders/Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 
ICL MRC Centre 
for Global 
Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University Press 
ODI SLH: 
Handwashin
g in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparednes
s 
Innovations 
  Social 
Developm
ent Direct 
C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health Policy 
and Planning  
Norwegian 
Institute of Public 
Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA Network Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE journals  Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer Nature       
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines  
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response  
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio  
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa  
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online courses Varies WHO 
Available 
now 
Standard precautions: 
Environmental cleaning 
and disinfection  
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis  
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School of 
Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications  
Mobile app   WHO 
Available 
now 
COVID-19: Pandemics, 
Modelling and Policy  
Online learning 2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course  
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks  
5 sessions 1h 30 International Initiative for 
Impact Evaluation (3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open online 
brief with Dr David 
Nabarro  
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods for 
detection, prevention, 
response and control  
Online learning 3 hours WHO 
Available 
now 
Responding to COVID-
19: Real-time training 
for the coronavirus 
disease outbreak  
Online learning Multiple 
self-paced 
course 
WHO 
25 May 2020 COVID-19: Tackling 
the Novel Coronavirus  
Online learning 3 weeks | 4 
hours 
weekly 
study 
FutureLearn LSHTM/UK 
PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 Diagnostics 
and Testing  
Online learning 3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application  
Online learning 5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians of 
Edinburgh  
Available 
now 
COVID-19 supporting 
online courses  
Online learning Multiple 
self-paced 
course 
BMJ Learning 
  
Suggested citation 
Millington, K.A. and Reddin, S. (2020). COVID-19 Health Evidence Summary No.100. K4D 
Evidence Summary. Brighton, UK: Institute of Development Studies. 
 
Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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